Close
Close
Finance News

Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock

3.09090909091
3.1 from 11 votes
Wednesday, February 14, 2018

CAMBRIDGE, Mass. -Ra Pharmaceuticals, Inc. (NASDAQ:RARX) ("Ra Pharma") announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. Ra Pharma expects to grant the underwriters a 30-day option to purchase up to $7.5 million of additional shares of its common stock.

Credit Suisse, Jefferies, and BMO Capital Markets are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey is acting as lead manager.

Ra Pharma intends to use the net proceeds from the offering, in addition to our existing cash resources, to fund its Phase 2 trial for RA101495 for gMG, other pipeline programs, and for working capital and general corporate purposes.

The securities described will be offered by Ra Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-221266), including a base prospectus. The securities will be offered only by means of a prospectus. A preliminary prospectus supplement related to the offering and a final prospectus related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplements and the accompanying prospectuses relating to the securities being offered may also be obtained, when available, from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Dept., One Madison Avenue, New York, NY 10010, by telephone at 800- 221-1037 or by email at newyork.prospectus@credit-suisse.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, telephone: (800) 414-3627, email: bmoprospectus@bmo.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade.

Contacts:
Investors:
Argot Partners
Natalie Wildenradt
Phone: 646-681-8192
Email: natalie@argotpartners.com
or
Media:
Argot Partners
David Rosen
Phone: 212-600-1902
Email: david.rosen@argotpartners.com

Source: Ra Pharmaceuticals
3.09090909091
3.1 from 11 votes
Free Newsletter
Trending News
Videos
by Abidemi Uruejoma
5 views
by Abidemi Uruejoma
18 views
by Abidemi Uruejoma
37 views